Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study.

Sara Lonardi,Filippo Pietrantonio,Alessandra Anna Prete,Marco Messina,Nicola Renzi,Domenico C. Corsi,Federica Urbano,Giovanni Luca Frassineti,M. Giulia Zampino,Monica Ronzoni,Mario Scartozzi,Mariaelena Casagrande,Alessandra Boccaccino,Francesca Bergamo,Michele Prisciandaro,Cosimo Rasola,Salvatore Corallo,Paola Del Bianco,Valentina Vettore,Vittorina Zagonel

Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study.

2020

4051Background: Advanced squamous cell anal carcinoma (advSCAC) is a rare disease with poor prognosis. No standard therapies beyond first line are currently available, yet a promising activity was ...

Keywords:

Squamous Cell Anal Carcinoma
Oncology
Cetuximab
locally advanced
Pathology
Avelumab
Internal medicine
Medicine
poor prognosis
Rare disease
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations